Our Science

Based on a decade of research, DGD Pharmaceuticals, Corp. is developing DGD1202, a first-in-class, orally available drug candidate, that inhibits activated EGFR dimerization, induces EGFR degradation, and promotes cell death in mutant EGFR (mtEGFR) lung cancers that are resistant to all current EGFR tyrosine kinase inhibitor (TKI) therapy.